EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting IL-6 in antibody-mediated kidney transplant rejection

Mehmet Kanbay iD, Berk Mizrak, Sidar Copur, Ezgi N Alper, Sebahat Akgul, Alberto Ortiz iD, Caner Susal

Clinical Kidney Journal · 01.05.2025 · 18 (5)

DOI: 10.1093/ckj/sfaf108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 15.04.2025. Verfasst von Mehmet Kanbay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, KUTTAM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin (IL)-6 is a major pro-inflammatory cytokine and central regulator of innate and adaptive immune responses. Clinical trials testing antibodies against IL-6 or its receptors have demonstrated its involvement in the pathogenesis of several autoimmune and inflammatory disorders and in the systemic inflammation and anemia associated to kidney failure and also in kidney allograft rejection. Additionally, the anti-IL-6 receptor antibody tocilizumab and the anti-IL-6 antibody clazakizumab have been studied for the treatment of naïve as well as resistant antibody-mediated kidney allograft rejection with mixed results in observational studies and early clinical development. Following promising results with a clazakizumab in a phase 2 placebo-controlled trial, a large phase 3 trial (IMAGINE) was terminated in 2024 for futility at interim analysis. Investigator-initiated clinical development continues in a smaller phase 3 trial testing tocilizumab (INTERCEPT). In this viewpoint article, we evaluate the pathophysiology of IL-6 in antibody-mediated kidney allograft rejection along with the current status of the clinical development of IL-6 targeting therapies for antibody-mediated kidney allograft rejection episodes within the wider frame of IL-6 targeting therapies in kidney failure that are considered the major causes of graft loss in kidney transplantation.

Schlagwörter

Stichwörter der Autor:innen

antibody-mediated rejectioncanakinumabinterleukin 6kidney transplantationtocilizumab

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey.
  • Transplant Immunology Research Center of Excellence TIREX, Koç University Hospital, Istanbul, Turkey.
  • Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.

ORCID-Profile: Mehmet Kanbay, Alberto Ortiz

Förderung

  • European Union
  • KUTTAM

Zitieren

APA

Kanbay, M., Mizrak, B., Copur, S., Alper, E. N., Akgul, S., Ortiz, A., & Susal, C. (2025). Targeting IL-6 in antibody-mediated kidney transplant rejection. Clinical Kidney Journal, 18(5). https://doi.org/10.1093/ckj/sfaf108

Vancouver

Kanbay M, Mizrak B, Copur S, Alper EN, Akgul S, Ortiz A, et al. Targeting IL-6 in antibody-mediated kidney transplant rejection. Clinical Kidney Journal. 2025;18(5). doi:10.1093/ckj/sfaf108

BibTeX
@article{Kanbay2025,
  author = {Kanbay, Mehmet and Mizrak, Berk and Copur, Sidar and Alper, Ezgi N and Akgul, Sebahat and Ortiz, Alberto and Susal, Caner},
  title = {Targeting IL-6 in antibody-mediated kidney transplant rejection},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {5},
  doi = {10.1093/ckj/sfaf108}
}
Kostenlos starten →